The potential of sestrins as therapeutic targets for diabetes.
The potential of sestrins as therapeutic targets for diabetes.
复制标题
DOI：
10.1517/14728222.2015.1044976
复制
发表时间：
2015
影响因子：
5.8
通讯作者：
Dong XC
中科院分区：
文献类型：
--
作者：
Dong XC
Sestrins(Sesn1/2/3)是一个具有多种生物学功能的小蛋白家族。除了最初确定的氧化还原酶活性外，Sestrins还具有氧化还原酶不依赖于酶的功能，包括激活AMP激活的蛋白激酶(AMPK)、抑制雷帕霉素复合体1的机制靶点(MTORC1)和激活mTORC2。由于这些激酶对代谢调节很重要，Sestrins作为糖尿病等代谢性疾病的潜在治疗靶点具有良好的前景。最近的数据与这一概念相符。在这篇社论中，我试图提供一些关于Sestrins在新陈代谢方面的主要发现的简要更新。
Sestrins (Sesn1/2/3) belong to a small protein family that has versatile biological functions. In addition to initially characterized oxidoreductase activity, sestrins also have oxidoreductase-independent functions, including activation of AMP-activated protein kinase (AMPK), inhibition of mechanistic target of rapamycin complex 1 (mTORC1), and activation of mTORC2. As these kinases are important for metabolic regulation, sestrins have a favorable profile as potential therapeutic targets for metabolic diseases such as diabetes. Recent data are in line with such a notion. In this editorial, I have attempted to provide some brief update on the major findings in regard to sestrins in metabolism.